Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva’s New CEO Levin Urges “Fiscal, Strategic Discipline,” Reduces 2012 Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

In a hastily scheduled, between-quarters update, Teva takes down its 2012 guidance issued only five months ago. New CEO Jeremy Levin promises a full strategic rendering by year end, announces long-time Teva exec Allan Oberman as new head of U.S. generics and establishment of a global compliance committee.

You may also be interested in...



Overhauling Teva: Conversations With Jeremy Levin And Michael Hayden

Teva CEO Jeremy Levin and the CSO he hired, Michael Hayden, want to re-focus the company on innovative R&D and selective generics opportunities, and that means an overhaul of the R&D organization and new priorities for business development. Levin and Hayden spoke to IN VIVO about their goals and shaping these activities following a widely anticipated investor briefing on December 11 in New York City.

Mesoblast Advances Stem-Cell Drugs As Catalysts Approach

Australian regenerative medicines company Mesoblast is working with its partner Teva to move a stem-cell treatment for congestive heart failure into Phase III clinical studies.

Second Quarter Earnings Calls, In Brief

As second quarter earnings announcement shift into high gear, companies announce changes to manufacturing, progress on their drug launch efforts and their intentions to ramp up business development efforts.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel